212197-74-5

Basic information

• Product Name: 5-CYANOFURAN-2-CARBOXYLICACID
• Synonyms: 5-CYANOFURAN-2-CARBOXYLICACID;2-Cyano-5-furancarboxylic acid;2-Furancarboxylic acid, 5-cyano-;5-cyano-2-furancarboxylic acid
• CAS NO: 212197-74-5
• Molecular Formula: C₆H₃NO₃
• Molecular Weight: 137.1
• Mol File: 212197-74-5.mol

Chemical Properties

• Boiling Point: 314℃
• Flash Point: 144℃
• Appearance: /
• Density: 1.47
• Storage Temp.: 2-8°C
• PKA: 2.23±0.10(Predicted)
• CAS DataBase Reference: 5-CYANOFURAN-2-CARBOXYLICACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CYANOFURAN-2-CARBOXYLICACID(212197-74-5)
• EPA Substance Registry System: 5-CYANOFURAN-2-CARBOXYLICACID(212197-74-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 212197-74-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
5-CYANOFURAN-2-CARBOXYLICACID is used as a synthetic intermediate for the production of various organic compounds due to its reactivity in forming carbon-carbon bonds and its ability to participate in ester or amide bond formation.
Used in Pharmaceutical Industry:
5-CYANOFURAN-2-CARBOXYLICACID is used as a building block in the development of pharmaceutical compounds, leveraging its chemical reactivity to create novel drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
5-CYANOFURAN-2-CARBOXYLICACID is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides, due to its potential to form a variety of chemical structures with bioactive properties.
Used in Material Science:
5-CYANOFURAN-2-CARBOXYLICACID is used as a component in the development of new materials, such as polymers and coatings, where its reactivity can contribute to the creation of materials with specific properties.
The specific applications and uses of 5-CYANOFURAN-2-CARBOXYLICACID would be determined by further research and development, as well as the detailed study and characterization of its physical and chemical properties, safety, and reactivity in various chemical contexts.

Upstream product

• 617-90-3 2-furancarbonitrile 
• 124-38-9 carbon dioxide 
• 54376-30-6 C₆H₅NO₄ 
• 13529-17-4 5-Formyl-2-furancarboxylic acid 
• 19158-51-1 P-toluenesulfonyl cyanide 

Downstream Products

• 885703-64-0 5-cyano-N-(4-(4-methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide 
• 854044-10-3 5-cyano-furan-2-carboxylic acid [2-(4-acetylamino-piperidin-1-yl)-phenyl]-amide 
• 852285-86-0 5-Cyano-furan-2-carboxylic acid [2-(1H-pyrazol-3-yl)-phenyl]-amide 
• 852285-85-9 5-Cyano-furan-2-carboxylic acid biphenyl-2-ylamide 
• 852285-84-8 5-Cyano-furan-2-carboxylic acid (2-furan-3-yl-phenyl)-amide 
• 852285-83-7 5-Cyano-furan-2-carboxylic acid (2-furan-2-yl-phenyl)-amide 

Relevant articles and documents

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

C-FMS KINASE INHIBITORS

The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

METHOD OF INHIBITING FLT3 KINASE

A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention (I), or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula (I): wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.

AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE

The invention relates to compounds of Formula (I), wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.

SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

C-fms kinase inhibitors

The invention is directed to compounds of Formulae I: wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Method for producing Grignard compounds

The invention relates to a process for preparing Grignard compounds of the formula I. The invention additionally relates to compounds of the formula I and to polymer-bound compounds of the formula Ia. The invention further relates to the use of the process for preparing substance libraries and to the use of the compounds of the formulae I and Ia in chemical synthesis.

C-FMS KINASE INHIBITORS

The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein t